Advanced search

  • Neurologia i Neurochirurgia Polska
  • Online first Update on diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) — recommendations of Section of Multiple Sclerosis and Neuroimmunology of Polish Neurological Society
Online first
Guidelines
Published online: 2024-12-18

open access

View PDF Download PDF file
Page views 108
Article views/downloads 86
Get Citation

Connect on Social Media

Connect on Social Media

Update on diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) — recommendations of Section of Multiple Sclerosis and Neuroimmunology of Polish Neurological Society

Beata Zakrzewska-Pniewska1, Halina Bartosik-Psujek2, Waldemar Brola3, Marek Gołębiowski4, Alicja Kalinowska5, Alina Kułakowska6, Dagmara Mirowska-Guzel7, Monika Nojszewska1, Aleksandra Podlecka-Piętowska1, Mariusz Stasiołek8, Sławomir Wawrzyniak9, Monika Adamczyk-Sowa10
DOI: 10.5603/pjnns.100945
Pubmed: 39692818

Abstract

Introduction. An expert panel of the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society has developed principles for the management of neuromyelitis optica spectrum disorders (NMOSD). These principles are based on expert opinion and data from the literature published up to May 2023. Recommendations were developed based on the results of the most recent clinical trials, guidelines of foreign and international scientific societies, and the authors’ clinical experience.

Clinical implications. The principles for diagnosing NMOSD are discussed, with particular emphasis on serological and neuroimaging diagnosis. Recommendations for the treatment of relapses and chronic immunosuppressive treatment, including the most recent methods of immunotherapy, are also presented. Additionally, the principles of monitoring treatment efficacy and safety are included. Therapy regimens are completed with recommendations for symptomatic treatment. The paper also includes an algorithm for vaccination in patients with NMOSD. Therapeutic management in pregnant women with NMOSD is discussed.

Keywords: recommendationsdiagnosis and treatmentneuromyelitis optica spectrum disordersNMOSD

Article available in PDF format

View PDF Download PDF file

References

  1. Devic E. Myelite aigue dorso-lombaire avec nevrite optique. Autopsie. Congres francais de Medecine. ; 1895: 434–439.
  2. Fujihara K. Neuromyelitis optica spectrum disorders: still evolving and broadening. Curr Opin Neurol. 2019; 32(3): 385–394.
    CrossRefPubMed
  3. Jarius S, Wildemann B. An early case of neuromyelitis optica: on a forgotten report by Jacob Lockhart Clarke, FRS. Mult Scler. 2011; 17(11): 1384–1386.
    CrossRefPubMed
  4. Lucchinetti CF, Guo Y, Popescu BF, et al. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol. 2014; 24(1): 83–97.
    CrossRefPubMed
  5. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007; 6(9): 805–815.
    CrossRefPubMed
  6. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999; 53(5): 1107–1114.
    CrossRefPubMed
  7. Graber DJ, Levy M, Kerr D, et al. Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation. 2008; 5: 22.
    CrossRefPubMed
  8. Jarius S, Aktas O, Ayzenberg I, et al. Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J Neurol. 2023; 270(7): 3341–3368.
    CrossRefPubMed
  9. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364(9451): 2106–2112.
    CrossRefPubMed
  10. Wingerchuk DM, Banwell B, Bennett JL, et al. International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85(2): 177–189.
    CrossRefPubMed
  11. Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation. 2011; 8: 184.
    CrossRefPubMed
  12. Ramanathan S, Reddel SW, Henderson A, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2014; 1(4): e40.
    CrossRefPubMed
  13. Jarius S, Ruprecht K, Kleiter I, et al. in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016; 13(1): 280.
    CrossRefPubMed
  14. Waters P, Woodhall M, O'Connor KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm. 2015; 2(3): e89.
    CrossRefPubMed
  15. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014; 82(6): 474–481.
    CrossRefPubMed
  16. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012; 79(12): 1273–1277.
    CrossRefPubMed
  17. Jarius S, Kleiter I, Ruprecht K, et al. in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. J Neuroinflammation. 2016; 13(1): 281.
    CrossRefPubMed
  18. Marignier R, Hacohen Y, Cobo-Calvo A, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 2021; 20(9): 762–772.
    CrossRefPubMed
  19. Ciotti JR, Eby NS, Wu GF, et al. Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica. Mult Scler Relat Disord. 2020; 45: 102399.
    CrossRefPubMed
  20. Hor JY, Asgari N, Nakashima I, et al. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol. 2020; 11: 501.
    CrossRefPubMed
  21. Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018; 15(1): 134.
    CrossRefPubMed
  22. Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023; 22(3): 268–282.
    CrossRefPubMed
  23. Carnero Contentti E, Okuda DT, Rojas JI, et al. MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease. J Neuroimaging. 2023; 33(5): 688–702.
    CrossRefPubMed
  24. Selmaj K, Selmaj I. Novel emerging treatments for NMOSD. Neurol Neurochir Pol. 2019; 53(5): 317–326.
    CrossRefPubMed
  25. Ayzenberg I, Kleiter I, Schröder A, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol. 2013; 70(3): 394–397.
    CrossRefPubMed
  26. Kleiter I, Traboulsee A, Palace J, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019; 381(22): 2114–2124.
    CrossRefPubMed
  27. Ringelstein M, Ayzenberg I, Harmel J, et al. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2015; 72(7): 756–763.
    CrossRefPubMed
  28. Zhang C, Zhang M, Qiu W, et al. TANGO Study Investigators. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020; 19(5): 391–401.
    CrossRefPubMed
  29. Borisow N, Mori M, Kuwabara S, et al. Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. Front Neurol. 2018; 9: 888.
    CrossRefPubMed
  30. Abboud H, Salazar-Camelo A, George N, et al. On-behalf of the Guthy-Jackson Foundation NMO International Clinical Consortium. Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders. J Neurol. 2022; 269(4): 1786–1801.
    CrossRefPubMed
  31. Jarius S, Paul F, Weinshenker BG, et al. Neuromyelitis optica. Nat Rev Dis Primers. 2020; 6(1): 85.
    CrossRefPubMed
  32. Tugizova M, Vlahovic L, Tomczak A, et al. New Therapeutic Landscape in Neuromyelitis Optica. Curr Treat Options Neurol. 2021; 23(4): 13.
    CrossRefPubMed
  33. Costello F. Neuromyelitis Optica Spectrum Disorders. Continuum (Minneap Minn). 2022; 28(4): 1131–1170.
    CrossRefPubMed
  34. Carnero Contentti E, Rojas JI, Cristiano E, et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Mult Scler Relat Disord. 2020; 45: 102428.
    CrossRefPubMed
  35. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010; 17(8): 1019–1032.
    CrossRefPubMed
  36. Juryńczyk M, Weinshenker B, Akman-Demir G, et al. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. J Neurol. 2016; 263(1): 140–149.
    CrossRefPubMed
  37. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology. 2003; 60(5): 848–853.
    CrossRefPubMed
  38. Kim SM, Kim SJ, Lee HJ, et al. Differential diagnosis of neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord. 2017; 10(7): 265–289.
    CrossRefPubMed
  39. Jasiak-Zatońska M, Michalak S, Kozubski W, et al. Diagnostic pitfalls in neuromyelitis optica spectrum disorders. Aktualności Neurologiczne. 2021; 21(3): 143–154.
    CrossRef
  40. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012; 78(9): 665–71; discussion 669.
    CrossRefPubMed
  41. Waters P, Reindl M, Saiz A, et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2016; 87(9): 1005–1015.
    CrossRefPubMed
  42. Melamed E, Levy M, Waters PJ, et al. Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015; 2(4): e134.
    CrossRefPubMed
  43. Jarius S, Franciotta D, Bergamaschi R, et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology. 2007; 68(13): 1076–1077.
    CrossRefPubMed
  44. Scott TF, Kassab SL, Pittock SJ. Neuromyelitis optica IgG status in acute partial transverse myelitis. Arch Neurol. 2006; 63(10): 1398–1400.
    CrossRefPubMed
  45. Sąsiadek M, Hartel M, Siger M, et al. Recommendations of the Polish Medical Society of Radiology and the Polish Society of Neurology for a protocol concerning routinely used magnetic resonance imaging in patients with multiple sclerosis. Neurol Neurochir Pol. 2020; 54(5): 410–415.
    CrossRefPubMed
  46. Flanagan EP, Weinshenker BG, Krecke KN, et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol. 2015; 72(1): 81–87.
    CrossRefPubMed
  47. Kim W, Park MSu, Lee SH, et al. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler. 2010; 16(10): 1229–1236.
    CrossRefPubMed
  48. Huh SY, Min JH, Kim W, et al. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. Mult Scler. 2014; 20(6): 695–704.
    CrossRefPubMed
  49. Tillema JM, Pirko I. Neuroradiological evaluation of demyelinating disease. Ther Adv Neurol Disord. 2013; 6(4): 249–268.
    CrossRefPubMed
  50. Solomon JM, Paul F, Chien C, et al. A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course. Ther Adv Neurol Disord. 2021; 14: 17562864211014389.
    CrossRefPubMed
  51. Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018; 89(4): 346–351.
    CrossRefPubMed
  52. Jiao Y, Cui L, Zhang W, et al. Plasma Exchange for Neuromyelitis Optica Spectrum Disorders in Chinese Patients and Factors Predictive of Short-term Outcome. Clin Ther. 2018; 40(4): 603–612.
    CrossRefPubMed
  53. Reeves HM, Winters JL. The mechanisms of action of plasma exchange. Br J Haematol. 2014; 164(3): 342–351.
    CrossRefPubMed
  54. Keegan M, Pineda AA, McClelland RL, et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002; 58(1): 143–146.
    CrossRefPubMed
  55. Elsone L, Panicker J, Mutch K, et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. 2014; 20(4): 501–504.
    CrossRefPubMed
  56. Galati A, Brown ES, Bove R, et al. Glucocorticoids for therapeutic immunosuppression: Clinical pearls for the practicing neurologist. J Neurol Sci. 2021; 430: 120004.
    CrossRefPubMed
  57. Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011; 77(7): 659–666.
    CrossRefPubMed
  58. Wei K, Nie Q, Zhu Y, et al. Different doses of Rituximab for the therapy of Neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. Mult Scler Relat Disord. 2022; 68: 104127.
    CrossRefPubMed
  59. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuro- myelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009; 66(9): 1128–1133, doi: 10.1001/ archneurol.2009. 175, indexed in Pubmed. ; 19752302.
  60. Montcuquet A, Collongues N, Papeix C, et al. NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP). Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler. 2017; 23(10): 1377–1384.
    CrossRefPubMed
  61. Zakrzewska-Pniewska B, Adamczyk-Sowa M, Brola W, et al. Leczenie i postępowanie objawowe w stwardnieniu rozsianym Rekomendacje Sekcji SM i Neuroimmunologii Polskiego Towarzystwa Neurologicznego. Polski Przegląd Neurologiczny. 2020; 15(4): 191–217.
    CrossRef
  62. Bove RM, Houtchens MK. Pregnancy Management in Multiple Sclerosis and Other Demyelinating Diseases. Continuum (Minneap Minn). 2022; 28(1): 12–33.
    CrossRefPubMed
  63. Nour MM, Nakashima I, Coutinho E, et al. Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder. Neurology. 2016; 86(1): 79–87.
    CrossRefPubMed
  64. D'Souza R, Wuebbolt D, Andrejevic K, et al. Pregnancy and Neuromyelitis Optica Spectrum Disorder - Reciprocal Effects and Practical Recommendations: A Systematic Review. Front Neurol. 2020; 11: 544434.
    CrossRefPubMed
  65. Kim W, Kim SH, Nakashima I, et al. Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology. 2012; 78(16): 1264–1267.
    CrossRefPubMed
  66. Anderson A, Singh J, Bove R. Neuroimaging and radiation exposure in pregnancy. Handb Clin Neurol. 2020; 171: 179–191.
    CrossRefPubMed
  67. Gur C, Diav-Citrin O, Shechtman S, et al. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol. 2004; 18(1): 93–101.
    CrossRefPubMed
  68. Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019; 34(3): 171–354.
    CrossRefPubMed
  69. Wind M, Gaasbeek AGA, Oosten LEM, et al. Therapeutic plasma exchange in pregnancy: A literature review. Eur J Obstet Gynecol Reprod Biol. 2021; 260: 29–36.
    CrossRefPubMed
  70. Wallach AI, Tremblay M, Kister I. Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder. Neurol Clin. 2021; 39(1): 35–49.
    CrossRefPubMed
  71. Mao-Draayer Y, Thiel S, Mills EA, et al. Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. Nat Rev Neurol. 2020; 16(3): 154–170.
    CrossRefPubMed
  72. Winkelmann A, Loebermann M, Barnett M, et al. Vaccination and immunotherapies in neuroimmunological diseases. Nat Rev Neurol. 2022; 18(5): 289–306.
    CrossRefPubMed
  73. Bühler S, Eperon G, Ribi C, et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly. 2015; 145: w14159.
    CrossRefPubMed
  74. Guptill JT, Juel VC, Massey JM, et al. Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis. Autoimmunity. 2016; 49(7): 472–479.
    CrossRefPubMed
  75. Furer V, Rondaan C, Heijstek M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020; 79(1): 39–52.
    CrossRefPubMed
  76. Huber F, Ehrensperger B, Hatz C, et al. Safety of live vaccines on immunosuppressive or immunomodulatory therapy-a retrospective study in three Swiss Travel Clinics. J Travel Med. 2018; 25(1).
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note